相似文献
1
Polidocanol for endovenous microfoam sclerosant therapy.
Expert Opin Investig Drugs. 2009 Dec;18(12):1919-27. doi: 10.1517/13543780903376163.
2
The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence.
Phlebology. 2014 Oct;29(9):608-18. doi: 10.1177/0268355513497709. Epub 2013 Jul 17.
3
Treatment of Truncal Incompetence and Varicose Veins with a Single Administration of a New Polidocanol Endovenous Microfoam Preparation Improves Symptoms and Appearance.
Eur J Vasc Endovasc Surg. 2015 Dec;50(6):784-93. doi: 10.1016/j.ejvs.2015.06.111. Epub 2015 Sep 16.
4
Sclerotherapy: a study comparing polidocanol in foam and liquid form.
Phlebology. 2010 Feb;25(1):44-9. doi: 10.1258/phleb.2009.008064.
5
Novel developments in foam sclerotherapy: Focus on Varithena® (polidocanol endovenous microfoam) in the management of varicose veins.
Phlebology. 2018 Apr;33(3):150-162. doi: 10.1177/0268355516687864. Epub 2017 Feb 6.
6
Clinical significance of cerebrovascular gas emboli during polidocanol endovenous ultra-low nitrogen microfoam ablation and correlation with magnetic resonance imaging in patients with right-to-left shunt.
J Vasc Surg. 2011 Jan;53(1):131-7. doi: 10.1016/j.jvs.2010.06.179. Epub 2010 Sep 22.
7
Sclerotherapy and foam sclerotherapy for varicose veins.
Phlebology. 2009 Dec;24(6):260-9. doi: 10.1258/phleb.2009.009050.
8
Microfoam sclerotherapy.
Semin Cutan Med Surg. 2005 Dec;24(4):175-83. doi: 10.1016/j.sder.2005.10.005.
9
Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2).
J Vasc Surg Venous Lymphat Disord. 2015 Jul;3(3):258-264.e1. doi: 10.1016/j.jvsv.2015.03.003. Epub 2015 May 6.
10
Comparative effectiveness of non-compounded polidocanol 1% endovenous microfoam (Varithena) ablation versus endovenous thermal ablation utilizing a systematic review and network meta-analysis.
J Vasc Surg Venous Lymphat Disord. 2024 Nov;12(6):101896. doi: 10.1016/j.jvsv.2024.101896. Epub 2024 Apr 26.
引用本文的文献
1
Consensus on Sclerotherapy for Patients With Hereditary Hemorrhagic Telangiectasia-Related Epistaxis.
JAMA Otolaryngol Head Neck Surg. 2025 Sep 1;151(9):881-887. doi: 10.1001/jamaoto.2025.2296.
2
Tranexamic acid-fatty alcohol polyoxyethylene ether conjugation/PVA foam for venous sclerotherapy vascular damage and inhibiting plasmin system.
Acta Pharm Sin B. 2025 Jun;15(6):3291-3304. doi: 10.1016/j.apsb.2025.03.032. Epub 2025 Mar 18.
3
Real-world use of polidocanol foam sclerotherapy for hemorrhoidal disease: insights from an international survey and systematic review with clinical practice recommendations.
Updates Surg. 2025 Jun 6. doi: 10.1007/s13304-025-02258-2.
4
Sclerotherapy for hemorrhoidal disease: Recent evolutions of an oldies goldy.
World J Gastroenterol. 2025 Feb 28;31(8):98704. doi: 10.3748/wjg.v31.i8.98704.
5
Enhanced sclerotherapy for vascular malformations: A dual-mechanism approach using in-situ forming PATDs gel.
Mater Today Bio. 2024 Nov 30;29:101376. doi: 10.1016/j.mtbio.2024.101376. eCollection 2024 Dec.
6
Embolo/sclerotherapy for the treatment of hand arteriovenous malformations: a single-center retrospective cohort experience.
Front Surg. 2023 Jun 16;10:1191876. doi: 10.3389/fsurg.2023.1191876. eCollection 2023.
7
Large Anorectal Venous Malformation Treated With Microfoam Therapy.
ACG Case Rep J. 2023 Mar 31;10(3):e01015. doi: 10.14309/crj.0000000000001015. eCollection 2023 Mar.
8
Effective viral-mediated lung gene therapy: is airway surface preparation necessary?
Gene Ther. 2023 Jun;30(6):469-477. doi: 10.1038/s41434-022-00332-7. Epub 2022 Mar 29.
9
A Novel Drug Self-Delivery System from Fatty Alcohol Esters of Tranexamic Acid for Venous Malformation Sclerotherapy.
Pharmaceutics. 2022 Feb 1;14(2):343. doi: 10.3390/pharmaceutics14020343.
10
The Efficacy and Health Economics of Different Treatments for Type 1 Cesarean Scar Pregnancy.
Front Pharmacol. 2022 Jan 28;13:822319. doi: 10.3389/fphar.2022.822319. eCollection 2022.
本文引用的文献
1
Clinical evaluation of sotradecol, a sodium alkyl sulfate solution, in the injection therapy of varicose veins.
Surg Gynecol Obstet. 1946 Nov;83(5):647-52.
2
Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study).
Phlebology. 2010 Jun;25(3):124-31. doi: 10.1258/phleb.2009.009043.
3
Sclerosing therapy of varicose veins with sotradecol (sodium tetradecyl sulfate).
N Y State J Med. 1947 Jun;47(12):1367.
4
Transient adverse events positively associated with patent foramen ovale after ultrasound-guided foam sclerotherapy.
Phlebology. 2009 Jun;24(3):114-9. doi: 10.1258/phleb.2008.008060.
5
More on microembolism and foam sclerotherapy.
N Engl J Med. 2008 Aug 7;359(6):656-7; author reply 657. doi: 10.1056/NEJMc080996.
6
Major neurological events following foam sclerotherapy.
Phlebology. 2008;23(4):189-92. doi: 10.1258/phleb.2007.007073.
7
Duplex ultrasound and efficacy criteria in foam sclerotherapy from the 2nd European Consensus Meeting on Foam Sclerotherapy 2006, Tegernsee, Germany.
Vasa. 2008 Feb;37(1):90-5. doi: 10.1024/0301-1526.37.1.90.
8
The lytic effects of detergent sclerosants on erythrocytes, platelets, endothelial cells and microparticles are attenuated by albumin and other plasma components in vitro.
Eur J Vasc Endovasc Surg. 2008 Aug;36(2):216-223. doi: 10.1016/j.ejvs.2008.03.001. Epub 2008 Apr 8.
9
Microembolism during foam sclerotherapy of varicose veins.
N Engl J Med. 2008 Apr 3;358(14):1525-6. doi: 10.1056/NEJMc0707265.
10
Prospective randomized efficacy of ultrasound-guided foam sclerotherapy compared with ultrasound-guided liquid sclerotherapy in the treatment of symptomatic venous malformations.
J Vasc Surg. 2008 Mar;47(3):578-84. doi: 10.1016/j.jvs.2007.11.026.
Zotero 插件